0.1802 -0.014 (-6.97%) | 12-21 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.39 | 1-year : | 0.53 |
Resists | First : | 0.34 | Second : | 0.46 |
Pivot price | 0.17 | |||
Supports | First : | 0.14 | Second : | 0.12 |
MAs | MA(5) : | 0.17 | MA(20) : | 0.18 |
MA(100) : | 0.28 | MA(250) : | 0.71 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 17.9 | D(3) : | 12.9 |
RSI | RSI(14): 45.5 | |||
52-week | High : | 1.58 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BWV ] has closed above bottom band by 37.1%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.17 - 0.17 | 0.17 - 0.17 |
Low: | 0.16 - 0.16 | 0.16 - 0.16 |
Close: | 0.17 - 0.17 | 0.17 - 0.17 |
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Tue, 17 Oct 2023
Blue Water Biotech names new CEO, CFO as company faces dual Nasdaq delisting notices - The Business Journals
Wed, 14 Jun 2023
Blue Water Biotech Expands Commercial Portfolio by - GlobeNewswire
Thu, 27 Apr 2023
Blue Water Biotech names Dr. Jay Newmark chief medical officer after Entadfi deal - The Business Journals
Tue, 25 Oct 2022
On the Horizon, Needle-Free Vaccines could Offer Better Protection and Access - BioSpace
Wed, 27 Jul 2022
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.37% - Investing.com
Fri, 08 Jul 2022
Top Recent IPOs: New Investment Opportunities - Investment U
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 19 (M) |
Shares Float | 14 (M) |
Held by Insiders | 17.6 (%) |
Held by Institutions | 23.4 (%) |
Shares Short | 23 (K) |
Shares Short P.Month | 60 (K) |
EPS | -1.09 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.56 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -30.3 % |
Return on Equity (ttm) | -101.7 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.75 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -12 (M) |
Levered Free Cash Flow | -18 (M) |
PE Ratio | -0.16 |
PEG Ratio | 0 |
Price to Book value | 0.29 |
Price to Sales | 0 |
Price to Cash Flow | -0.27 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |